Attendees will have the opportunity to evaluate amyloid and tau data in specific clinical and clinical research contexts, including review of typical findings in AD dementia, mild cognitive impairment due to AD, and in clinically normal individuals. This includes further elucidation of factors that underlie relationships between amyloid and tau deposition, cognitive decline, and dementia progression that provide a more informed understanding of individual patient trajectories. These efforts will also be related to familial forms of the disease, Down Syndrome, and to non-AD processes (i.e., fronto-temporal lobar degeneration and Lewy Body dementia). Further study of “real world” research participants will be discussed that includes people from diverse, ethnic and/or racial minority, and disadvantaged groups.

Particular attention will be given to the assessment of longitudinal amyloid and tau PET data as it relates to methods of analysis and comparison to other domains of data, including structural and functional brain imaging data, and clinical and cognitive outcomes. An ongoing topic of importance is the relative value of PET versus other detection strategies (e.g., MRI volumetry and biofluid biomarkers).

Attendees will also continue to have the opportunity the better understand methodology that can be used to optimize participant selection and conduct of AD therapeutic trials. Important topics relate to improved understanding of how in vivo metrics (imaging and non-imaging) and cognition change in response to AD therapeutic treatment (cross-sectionally and longitudinally) and how to better identify those most vulnerable to treatment side-effects, such as anti-amyloid related imaging abnormalities.